The Combination of Bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) is highly active in advanced colorectal.

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

Waterfall plot analysis of XELOX or XELIRI

1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

Intergroup trial CALGB 80101

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

RANDOMIZED PHASE II TRIAL COMPARING FOLFIRINOX (5FU/LEUCOVORIN, IRINOTECAN AND OXALIPLATIN) VS GEMCITABINE AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC.

ESMO/ECCO Presidential Session III

Capecitabine versus Bolus 5-FU/Leucovorin as Adjuvant Therapy for Colon Cancer: X-ACT Trial Results James Cassidy, MD Colorectal Cancer Update Think Tank.

Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1 / NO16966, a randomized phase III trial in first-line metastatic.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.

Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.

Poster #382 XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,

Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,

Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC)

NSABP Overall Survival and Updated Disease-Free Survival Results of the NSABP C-08 Trial Assessing Bevacizumab in Stage II & III Colon Cancer CJ Allegra,

Niall C. Tebbutt International randomised phase III study of capecitabine, bevacizumab, and mitomycin C in first-line treatment of metastatic colorectal.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.

EORTC OSN/CTOS11 Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final.

P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

A three-arm randomized phase III trial of FOLFOX4 vs FOLFOX4 + bevacizumab vs XELOX + bevacizumab in the adjuvant treatment of patients with stage III.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah on behalf of AVAGAST investigators AVAGAST: a randomized, double-blind.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis.

Alessandra Gennari, MD PhD

Vahdat L et al. Proc SABCS 2012;Abstract P

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Barrios C et al. SABCS 2009;Abstract 46.

Nab-paclitaxel in Ovarian Cancer

First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.

1 Sunnybrook Odette Cancer Centre, University of Toronto, Canada

for the Cancer and Leukemia Group B

and the NSABP Investigators

1Sunnybrook Health Sciences Centre, University of Toronto, Canada

Presentation transcript:

The Combination of Bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) is highly active in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604) A. Reinacher-Schick 1, S. Kubicka 2, W. Freier 3, D. Arnold 4, G. Dietrich 5, M. Geißler 6, S. Hegewisch-Becker 7, U. Graeven 8, H.-J. Schmoll 4 and W. Schmiegel 1, Ruhr University Bochum 1, University Hannover 2, Center of Oncology Hildesheim 3, Martin-Luther- University Halle-Wittenberg 4, Hospital Bietigheim, Bietigheim-Bissingen 5, Community Hospital Esslingen 6, Center of Oncology Eppendorf, Hamburg 7, Maria Hilf Hospital Mönchengladbach 8, Germany

Addition of Bevacizumab to 5FU/FA/irinotecan 1 and 5FU/FA/oxaliplatin 2,3 improves progression free survival (PFS) in advanced CRC (aCRC) Efficacy of Capecitabine/Oxaliplatin (CapOx) is similar to 5-FU/FA/Oxaliplatin Data on Capecitabine/Irinotecan (CapIri) combinations remains controversial, due to toxicity Hurwitz, N Engl J Med 2004; 2 Giantonio, JCO 2007; 3 Saltz, JCO 2008; 4 Fuchs, JCO 2007; 5 Köhne, Ann Oncol 2008; 6 Grothey, ASCO 2003; 7 Koopman, Lancet 2007 Background

Aim To investigate whether bevacizumab in combination with CapOx or CapIri is effective for patients with aCRC

Study Design Open-label, multicenter, randomized phase II study Primary endpoint: Rate of pts. without disease progression at 6 months: Exclude insufficient activity (defined as rate < 60%) Secondary endpoints: Overall survival, toxicity, resectability of liver/lung mets.

Main eligibility criteria - written informed consent - histologically proven aCRC, measurable lesion (RECIST) - Age > 18 years - ECOG performance status < 2 - Adequate haematological, renal and hepatic function - no previous systemic immunotherapy or chemotherapy (except (neo)adjuvant therapy for non-metastatic disease > 6 months) - history of thrombosis or severe bleeding < 6 months, bleeding diathesis, therapeutic anticoagulation - proteinuria < +1 by dipstick urin analysis

Treatment protocol Arm A: d 1 d 15 Oxaliplatin 130mg/m 2, 120min i.v. Bevacizumab 7,5 mg/kg i.v. Capecitabine 1000mg/m 2 p.o., 2x daily Arm B: (*) Irinotecan 200mg/m 2, 30min i.v. Bevacizumab 7,5 mg/kg i.v. Capecitabine 800mg/m 2 p.o., 2x daily q 3wks note dose reduction of CapIri compared to previous trials for safety reasons

Patient accrual observed expected

Baseline characteristics (n=247) No. Patients Arm A 127 Arm B 120 Median age (range), years64 (27-83)64.5 (30-82) Distribution of age, % < 40 years years years years years2922 > 80 years22 Male, female %66 / 3467 / 33 ECOG Performance status, % Prior adjuvant therapy, % No7779 Yes2321

Treatment characteristics (n=247) Number of pats. Arm A 127 Arm B 120 Total 247 Number of cycles (evaluable pats.) Mean no. of cycles (+/- SD) 9.1 (+/- 6.7)10.6 (+/-7.1)9.9 (+/-6.9) Range Median899

Reasons for end of treatment, EOT (n=222) Reason for EOT n Arm A 116 Arm B 108 Total 222 Disease Progression46 (40%)35 (32%)81 (36%) Progression free70 (60%)73 (68%)143 (64%) - toxicity27 (39%)12 (16%)39 (27%) - SAE5 (7%)8 (11%)13 (9%) - death, not tumor related 4 (6%)-4 (3%) - protocol violation2 (3%)5 (7%)7 (5%) - consent withdrawn11 (16%)14 (19%)25 (17%) - lost to follow-up1 (1%)2 (3%)3 (2%) - Resection/Ablation4 (6%)6 (8%)10 (7%) - Other16 (23%)26 (36%)42 (29%) *end of treatment information available for n=222 pts.

CTC V. 3.0 Grade 3 and 4 Toxicities (n=247) Related toxicities Arm A (127) 3°/4° [%] Arm B (120) 3°/4° [%] Diarrhoea21/016/0 Sensory neuropathy24/10 Hand-Foot-Syndrome11/08/0 Neutropenia 2/08/2 Thrombocytopenia6/00 Fatigue2/13/0 Ileus2/12/0 Nausea3/0 Vomiting4/05/0

AEs of special interest (n=247) AEs of special interest (Bev) Arm A (127) 3°/4° [%] Arm B (120) 3°/4° [%] Thrombosis/Embolism - venous access thrombosis - other (incl. pulmonary emb.) 3/2 1/0 2/2 4/1 1/0 3/1 Hypertension4/03/0 Cardiac ischemia/infarction00/1 Hemorrhage/bleeding (GI)1/00

Best overall response* (n=247) Arm A % of patients (n =127) Arm B % of patients (n =120) CR 56 PR 4849 SD 2928 PD 56 NE/NA** 1311 *ITT, RECIST criteria, investigator‘s assessment; **not evaluated/not available

PFS rate after 6 months: Primary endpoint Arm A % of patients (n =127) Arm B % of patients (n =120) PFS rate/6 mo.7684

Progression free survival (PFS) - ITT analysis months rate without progression

months Survival rate Overall survival (OS) - ITT analysis

Conclusion Both regimens, CapOx/Bev and CapIri/Bev, are highly active in aCRC. The dose reduction of CapIri/Bev may lead to a favourable toxicity profile compared to previous capecitabine/irinotecan trials seemingly without compromising efficacy The CapIri/Bev arm - compared to the CapOx/Bev arm - seems to be associated with higher cycle numbers and a tendency towards longer PFS

Acknowledgements We would like to thank - the patients and their families - the co-investigators - the study nurses and data monitors - Roche Pharma AG and Sanofi-Aventis for financial support